Conditions: Morphea Localized Scleroderma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea. Skin biopsies of morphea lesions before and after treatment with topical calcipotriene 0.005% ointment will be analyzed for changes in RNA and protein. A skin biopsy of unaffected skin will also be obtained and used for a control. This is an initial study to look at the molecular effects of topical calcipotriene on human morphea-involved skin. This study will look at the differences between affected and unaffected skin. This study also will look at clinical outcomes in morphea patients and determine if there are any clinical predictors for improvement with the medication.

Detailed description:

Arms:
arm 1: Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects

Interventions: intervention 1: topical calcipotriene 0.005% ointment
Intervention descriptions: intervention 1: Affected area will be treated twice daily for 3 months

Protocol document: